Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity
- PMID: 17164783
- DOI: 10.1038/sj.mt.6300039
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity
Abstract
Oncolytic viruses capable of tumor-selective replication and cytolysis have shown early promise as cancer therapeutics. However, the host immune system remains a significant obstacle to effective systemic administration of virus in a clinical setting. Here, we demonstrate the severe negative impact of the adaptive immune response on the systemic delivery of oncolytic vesicular stomatitis virus (VSV) in an immune-competent murine tumor model, an effect mediated primarily by the neutralization of injected virions by circulating antibodies. We show that this obstacle can be overcome by administering virus within carrier cells that conceal viral antigen during delivery. Infected cells were delivered to tumor beds and released virus to infect malignant cells while sparing normal tissues. Repeated administration of VSV in carrier cells to animals bearing metastatic tumors greatly improved therapeutic efficacy when compared with naked virion injection. Whole-body molecular imaging revealed that carrier cells derived from solid tumors accumulate primarily in the lungs following intravenous injection, whereas leukemic carriers disseminate extensively throughout the body. Furthermore, xenogeneic cells were equally effective at delivering virus as syngeneic cells. These findings emphasize the importance of establishing cell-based delivery platforms in order to maximize the efficacy of oncolytic therapeutics.
Similar articles
-
Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.Mol Ther. 2007 Jan;15(1):114-22. doi: 10.1038/sj.mt.6300020. Mol Ther. 2007. PMID: 17164782
-
Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.Laryngoscope. 2007 Feb;117(2):210-4. doi: 10.1097/01.mlg.0000246194.66295.d8. Laryngoscope. 2007. PMID: 17204993
-
Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.J Virol. 2015 Jul;89(13):6711-24. doi: 10.1128/JVI.00709-15. Epub 2015 Apr 15. J Virol. 2015. PMID: 25878115 Free PMC article.
-
Vesicular stomatitis virus: re-inventing the bullet.Trends Mol Med. 2004 May;10(5):210-6. doi: 10.1016/j.molmed.2004.03.003. Trends Mol Med. 2004. PMID: 15121047 Review.
-
[Vesicular stomatitis virus in the fight against cancer].Med Sci (Paris). 2013 Feb;29(2):175-82. doi: 10.1051/medsci/2013292015. Epub 2013 Feb 28. Med Sci (Paris). 2013. PMID: 23452604 Review. French.
Cited by
-
Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis.Front Pharmacol. 2022 Nov 14;13:1023533. doi: 10.3389/fphar.2022.1023533. eCollection 2022. Front Pharmacol. 2022. PMID: 36452227 Free PMC article.
-
Synergistic interaction between oncolytic viruses augments tumor killing.Mol Ther. 2010 May;18(5):888-95. doi: 10.1038/mt.2010.44. Epub 2010 Mar 16. Mol Ther. 2010. PMID: 20234341 Free PMC article.
-
VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.Mol Ther. 2010 Dec;18(12):2094-103. doi: 10.1038/mt.2010.188. Epub 2010 Sep 14. Mol Ther. 2010. PMID: 20842105 Free PMC article.
-
Use of Heterologous Vesiculovirus G Proteins Circumvents the Humoral Anti-envelope Immunity in Lentivector-Based In Vivo Gene Delivery.Mol Ther Nucleic Acids. 2019 Sep 6;17:126-137. doi: 10.1016/j.omtn.2019.05.010. Epub 2019 May 28. Mol Ther Nucleic Acids. 2019. PMID: 31254925 Free PMC article.
-
Vesiculovirus neutralization by natural IgM and complement.J Virol. 2014 Jun;88(11):6148-57. doi: 10.1128/JVI.00074-14. Epub 2014 Mar 19. J Virol. 2014. PMID: 24648451 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources